Fundraising FoxMEI Pharma
San Diego, US · Delaware corporation · 10 known investors
Find your way into MEI Pharma
Each arrow is one introduction. Sign up to fill in the first one.
Ask Katie Glenn to introduce you to Brian G. Drazba
You →Katie · together at Insight Imaging →Brian
Ask Jamie Chen to introduce you to David M. Urso
You →Jamie · together at MEI Pharma →David
Ask Sam Okafor to introduce you to Justin J. File
You →Sam · together at Lite Strategy →Justin
Sign up to find every way you can get introduced to MEI Pharma
- Your email: who you already know at MEI Pharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the MEI Pharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Lite Strategy, Inc. (NASDAQ: LITS) is a publicly traded treasury company that accumulates and manages Litecoin (LTC) holdings, aiming to increase LTC exposure per share for its shareholders. It positions itself as a way for public-market investors to gain exposure to Litecoin.
Founders & leadership
Board
Investors · 10
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: GSR's portfolio page · Not right? Tell us
How we know: funding news · biocentury.com · Not right? Tell us
How we know: Primitive Ventures's portfolio page · Not right? Tell us
How we know: biocentury.com · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$75M disclosed across 1 of 2 rounds · 2018–2025
▶$75MraisedMay 2018 · 20 investors · PharmaceuticalsRule 506(b)
- Frederick W. DriscollDirector
- Christine A. WhiteDirector
- David M. UrsoExecutive Officer
- Nicholas R. GloverDirector
- William D. RueckertDirector
- Daniel P. GoldExecutive Officer, Director
- Kevan E. ClemensDirector
- Thomas C. ReynoldsDirector
- Robert D. MassExecutive Officer
- Brian G. DrazbaExecutive Officer
- Charles V. Baltic IIIDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $4.5M
- Placement agents
- Laidlaw & Company (UK) Ltd., Suntrust Investment Services, Inc., Oppenheimer & Co. Inc., Wells Fargo Securities, LLC, Stifel, Nicolaus & Company, Incorporated, BTIG, LLC
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MEI Pharma do?
- Lite Strategy, Inc. (NASDAQ: LITS) is a publicly traded treasury company that accumulates and manages Litecoin (LTC) holdings, aiming to increase LTC exposure per share for its shareholders. It positions itself as a way for public-market investors to gain exposure to Litecoin.
- Who are MEI Pharma's investors?
- MEI Pharma's investors include 3B Future Health Fund, Aisling Capital, GSR, New Enterprise Associates (NEA), Primitive Ventures, Amzak Health, Biotechnology Value Fund, Vivo Capital.
- How much funding has MEI Pharma raised?
- MEI Pharma has disclosed $75M raised across 1 of its 2 known rounds.
- Where is MEI Pharma headquartered?
- MEI Pharma is headquartered in San Diego, US.